{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:55:03Z","timestamp":1783698903990,"version":"3.55.0"},"reference-count":39,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background and Objective: Bladder cancer (BC) is the ninth most common malignancy worldwide. Squamous cell carcinoma (SqCC), a rare histological variant, accounts for approximately 2\u20135% of all BC cases. Compared to urothelial carcinoma, the predominant subtype, research on SqCC remains limited and shows inconsistent findings regarding prognosis. This study aimed to compare survival outcomes between patients with SqCC and those with pure urothelial carcinoma (PUC). Methods: This retrospective, observational study analyzed pathology reports from 2549 transurethral resections of bladder tumors and 632 cystectomies performed at our institution between 1 December 2010 and 31 December 2023. Following pathological re-evaluation, 33 patients with SqCC and 132 with PUC were identified. After 1:3 propensity score matching, 20 patients with SqCC and 58 with PUC were included in the final analysis. Demographic, clinicopathological features, and survival outcomes were compared between groups. Results: The median follow-up was 2.31 years (range: 0.17\u201313.50). No significant differences in baseline demographic or clinical characteristics were observed, except for the type of surgery. Kaplan\u2013Meier analysis demonstrated no significant differences in disease-free survival (DFS; p = 0.961) or overall survival (OS; p = 0.847) between SqCC and PUC groups. Multivariate Cox regression analysis identified T stage, nodal involvement, and adjuvant chemotherapy (CT) as independent predictors of DFS, while sex and metastasis at diagnosis were significant predictors of OS. Conclusion: Survival outcomes (DFS and OS) did not significantly differ between patients with SqCC and patients with PUC. Prognosis was more closely associated with disease stage at diagnosis, sex, and adjuvant CT. Further large-scale studies are warranted.<\/jats:p>","DOI":"10.3390\/curroncol32070394","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:26:53Z","timestamp":1752229613000},"page":"394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival Outcomes in Patients with Squamous Cell Carcinoma of the Urinary Bladder: A Propensity Score-Matched Analysis"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2444-6587","authenticated-orcid":false,"given":"Alper","family":"Coskun","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-0870","authenticated-orcid":false,"given":"Ahmet Bilgehan","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7864-6694","authenticated-orcid":false,"given":"Selva","family":"Kabul","sequence":"additional","affiliation":[{"name":"Department of Pathology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Abdurrahman","family":"Celik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2079-3350","authenticated-orcid":false,"given":"Mursel","family":"Sali","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-7151","authenticated-orcid":false,"given":"Ender Eren","family":"Ozcelik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3931-0191","authenticated-orcid":false,"given":"Adem","family":"Deligonul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"Cubukcu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-910X","authenticated-orcid":false,"given":"Meral","family":"Kurt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursel","family":"Savci","sequence":"additional","affiliation":[{"name":"Department of Radiology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turkkan","family":"Evrensel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismet","family":"Yavascao\u011flu","sequence":"additional","affiliation":[{"name":"Department of Urology, Uludag University Faculty of Medicine, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"04109","DOI":"10.7189\/jogh.13.04109","article-title":"The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040","volume":"13","author":"Zhang","year":"2023","journal-title":"J. Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.3889\/oamjms.2019.857","article-title":"Schistosomiasis and Bladder Cancer in Egypt: Truths and Myths","volume":"7","author":"Amin","year":"2019","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"28408","DOI":"10.18632\/oncotarget.16083","article-title":"The prognostic value of histological subtype in patients with metastatic bladder cancer","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What Is the Significance of Variant Histology in Urothelial Carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/j.clgc.2020.01.002","article-title":"A California Cancer Registry Analysis of Urothelial and Non-urothelial Bladder Cancer Subtypes: Epidemiology, Treatment, and Survival","volume":"18","author":"Martin","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2020.07.011","article-title":"Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities","volume":"19","author":"Deuker","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bell, S.D., Quinn, A.E., Bajo, A., Mayberry, T.G., Cowan, B.C., Marrah, A.J., Wakefield, M.R., and Fang, Y. (2025). Squamous Cell Bladder Cancer: A Rare Histological Variant with a Demand for Modern Cancer Therapeutics. Cancers, 17.","DOI":"10.3390\/cancers17020169"},{"key":"ref_10","first-page":"158","article-title":"Bilharziasis and bladder cancer: A time trend analysis of 9843 patients","volume":"19","author":"Gouda","year":"2007","journal-title":"J. Egypt Natl. Cancer Inst."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.urolonc.2015.07.018","article-title":"Urothelial carcinoma with squamous differentiation\u2014The pathologists\u2019 perspective","volume":"33","author":"Gellert","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.clgc.2023.05.019","article-title":"Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder","volume":"21","author":"Agrawal","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/cncr.22853","article-title":"Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: A contemporary review of The University of Texas M D Anderson Cancer Center experience","volume":"110","author":"Kassouf","year":"2007","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10147-004-0457-6","article-title":"Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: A review of etiological features, natural history, and management","volume":"10","author":"Zaghloul","year":"2005","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"353.e17","DOI":"10.1016\/j.urolonc.2019.01.020","article-title":"The impact of squamous histology on survival in patients with muscle-invasive bladder cancer","volume":"37","author":"Matulay","year":"2019","journal-title":"Urol. Oncol."},{"key":"ref_16","first-page":"38","article-title":"A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database","volume":"15","author":"Michalski","year":"2018","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00345-012-0872-7","article-title":"Do pure squamous cell carcinomas and urothelial carcinomas have similar prognosis after radical cystectomy?","volume":"31","author":"Balci","year":"2013","journal-title":"World J. Urol."},{"key":"ref_18","first-page":"3865","article-title":"The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy","volume":"26","author":"Kastritis","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.urology.2008.11.042","article-title":"Urothelial carcinoma versus squamous cell carcinoma of bladder: Is survival different with stage adjustment?","volume":"73","author":"Scosyrev","year":"2009","journal-title":"Urology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: Impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s00345-021-03788-1","article-title":"Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort","volume":"39","author":"Weyerer","year":"2021","journal-title":"World J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e3181ec86b3","article-title":"Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists","volume":"34","author":"Sangoi","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"372.e21","DOI":"10.1016\/j.urolonc.2024.05.020","article-title":"Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer","volume":"42","author":"Campbell","year":"2024","journal-title":"Urol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.juro.2013.05.040","article-title":"The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer?","volume":"190","author":"Linder","year":"2013","journal-title":"J. Urol."},{"key":"ref_25","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group (2022). Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur. Urol., 81, 50\u201361."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102100","DOI":"10.1016\/j.clgc.2024.102100","article-title":"Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer","volume":"22","author":"Koehne","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1097\/JS9.0000000000001954","article-title":"The role of adjuvant chemotherapy after radical surgery in patients with lymph node-positive bladder cancer or locally advanced (pT3, pT4a) bladder cancer: A meta-analysis and systematic review","volume":"110","author":"Chen","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4111\/icu.2019.60.2.64","article-title":"Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials","volume":"60","author":"Kim","year":"2019","journal-title":"Investig. Clin. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4103\/jcrt.jcrt_875_21","article-title":"The impact of patient sex on characteristic-adjusted bladder cancer prognosis","volume":"17","author":"Zhao","year":"2021","journal-title":"J. Cancer Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00345-022-04116-x","article-title":"Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: A systematic review and meta-analysis","volume":"41","author":"Mori","year":"2023","journal-title":"World J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MOU.0000000000000606","article-title":"The impact of gender on oncologic outcomes of bladder cancer","volume":"29","author":"Mun","year":"2019","journal-title":"Curr. Opin. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes","volume":"81","author":"Abrahamsson","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1593\/neo.121956","article-title":"Loss of Sh3gl2\/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior","volume":"15","author":"Majumdar","year":"2013","journal-title":"Neoplasia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.urolonc.2015.06.006","article-title":"Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: A paradigm for molecular subtyping of urothelial cell carcinoma of the bladder","volume":"33","author":"Adam","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bju.15510","article-title":"Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: A propensity score matching analysis","volume":"130","author":"Kobayashi","year":"2022","journal-title":"BJU Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"499.e1","DOI":"10.1016\/j.clgc.2022.05.001","article-title":"Efficacy of Pembrolizumab in Patients with Variant Urothelial Carcinoma: A Multicenter Retrospective Study","volume":"20","author":"Minato","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/j.clgc.2023.05.007","article-title":"Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors or Enfortumab Vedotin","volume":"21","author":"Jindal","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/curroncol31020064","article-title":"Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study","volume":"31","author":"Minato","year":"2024","journal-title":"Curr. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:07:39Z","timestamp":1760033259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["curroncol32070394"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32070394","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}